chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At 10:02 am approximately in 14 minutes after being vaccinated patient ( at 10:48 am) developed epilepsy seizure that lasted for 5 minutes. Paramedics arrived to take care of the patient, no treatment was administered. Patient declined hospitalization and was taken home by her partner after she recovered from the seizure. Per patient, she has seizures every 3 month, and she was on her 12th week on the day of the vaccination. Pt takes topiramate for seizure control. Dose of the medication is unknown to me.
Redness, swelling & itching at injection site- BENADRYL 25 mg PO given @ 8:30 pm.  Zyrtec 10 mg given PO @ 11:00 am.
I had a flu vaccine on a friday afternoon. No other shots. was not ill. Woke up saturday morning with vertigo and nausea. As of now, it is sunday evening and vertigo and nausea are unabated.
felt a little bit dizzy; lightheaded; a little clammy; had tingling in the legs; general malaise; This is a spontaneous report from a contactable physician, the patient. A male patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), Lot number: EK5730 & Expiry: 31Mar2021, via an unspecified route of administration on 19Dec2020 (at an unspecified age) as a single dose for COVID-19 immunization. Medical history included severe allergic reaction to a plant, reported as 23 years ago, and he has not had any other type of allergic reaction and hasn't had any reactions to any vaccine. Concomitant medications were not reported. On 19Dec2020, reported as within 10 minutes of receiving the vaccine, the patient felt a little bit dizzy, lightheaded, a little clammy, and had tingling in the legs, all of which went away quickly afterwards, within 5 minutes.  The patient also had the typical side effects after receiving the vaccine such as general malaise for 24 hours. He had felt fine ever since then. The patient was supposed to receive his second dose "tonight or tomorrow morning" and queried whether there was any guidance on pre-medicating with diphenhydramine (BENADRYL). The clinical outcome of the events felt a little bit dizzy, lightheaded, a little clammy, had tingling in the legs, and general malaise were resolved on Dec2020.
Site: Redness at Injection Site-Mild, Site: Swelling at Injection Site-Mild, Additional Details: Skin infection from covid vaccine that began to weep and puss, went to er and given rx for doxycycline, it is currently improving and will be clear
I95.9 HYPOTENSION 12/5/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.00 ACUTE RESPIRATORY FAILURE 10/17/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.11 CHRONIC HYPOXEMIC RESPIRATORY FAILURE 12/5/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 12/13/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.90 RESPIRATORY FAILURE, UNSPECIFIED ACUITY 11/28/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE J96.91 HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY 10/22/2022 ACUTE HYPOXEMIC RESPIRATORY FAILURE
delayed injection site fever; arm sore; delayed injection site bad itching; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE WARMTH (delayed injection site fever), VACCINATION SITE PRURITUS (delayed injection site bad itching) and VACCINATION SITE PAIN (arm sore) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041620A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (no reported medical history).    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (delayed injection site bad itching). On 03-Feb-2021, the patient experienced VACCINATION SITE WARMTH (delayed injection site fever) and VACCINATION SITE PAIN (arm sore). At the time of the report, VACCINATION SITE WARMTH (delayed injection site fever), VACCINATION SITE PRURITUS (delayed injection site bad itching) and VACCINATION SITE PAIN (arm sore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported  Treatment for the events included ice and hydrocortisone cream.
Fatigue, fever, chills, rash, vasculitus, mouth sores, joint pain, breathing problems.
A localized reaction occurred the day after the patient recieved an intramuscular injection of Prevnar 13 in his left deltoid. The patient noticed an area just below the injection site which consisted of about a 2 inch diameter area of bruising or bleeding under the skin.  The patient reported no pain or discomfort at the area, only visual signs of bruising.  The patient was being seen by his physician several days later for a routine diabetes check up and asked the doctor about the reaction to the vaccine.  The doctor stated to the patient that the reaction of bruising/bleeding under the skin was normal since he was taking the blood thinner Effient as well as an aspirin every day.  Neither the patient nor the doctor showed any signs of concern and no treatment was provided.
High fever, swollen area around wound (size of golf ball), wound (size of nickel), throbbing sensation at site.
Nurse called reporting possibly administered doses of improperly stored VARIVAX to unspecified patients.; Nurse called reporting possibly administered doses of improperly stored VARIVAX to unspecified patients.; No adverse affects reported.; This spontaneous report was received from a nurse, referring to an unspecified number of patients of unknown ages and gender. The patients' pertinent medical histories, concurrent conditions, previous drug reactions/allergies, and concomitant medications were not reported.  On unspecified dates, the patients were possibly vaccinated with improperly stored doses of varicella virus vaccine live (Oka/Merck) (VARIVAX) (lot number S019462, which has been verified to be valid, expiration date reported and validated as 24-JUN-2021), as prophylaxis (routes of administration, dosage regimens and anatomical locations were not reported) (circumstance or information capable of leading to medication error and product storage error). The administered dose of the vaccine experienced a temperature excursion of 5.7 degrees Fahrenheit for 25 minutes, as recorded by a data logger. There was a previous temperature excursion, however if was not specified. No adverse effects reported.  This case has been considered as non-valid due to unspecified number of unspecified patients.
This case was reported by a pharmacist via sales rep and described the occurrence of fever in a male patient who received Shingrix for prophylaxis. In June 2018, the patient received the 1st dose of Shingrix. On an unknown date, less than a year after receiving Shingrix, the patient experienced fever, pain, chills and influenza-like symptoms. On an unknown date, the outcome of the fever, pain, chills and influenza-like symptoms were recovered/resolved. It was unknown if the reporter considered the fever, pain, chills and influenza-like symptoms to be related to Shingrix. Additional details were provided as follows: The age at vaccination was not reported. The reporter received the Shingrix shot personally. The patient experienced pain, low grade fever, chills and flu like symptoms, which resolved in about 24 hours. The reporter could not think of any other reason for the symptoms. The registered pharmacist did the reporter agree to follow up from Glaxosmithkline.
While at home suddenly became very poorly responsive to mom, no eye contact, no vocalization, "looked empty".  Lasted about 1.5 hrs the resolved completely and has been normal since.
Dizzy. Stumbled to floor.  Subsequently unstable on my feet. 24 sessions of physical therapy. Feeling relatively better but still need to walk with a cane
Herpes Zoster Ophthalmicus; Information has been received from a lawyer referring to a patient of unknown age and gender. Information about concurrent condition, history condition and concomitant medication was not reported. On or around 30-DEC-2014, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX) (date not reported), the patient suffered a bad case of herpes zoster ophthalmicus. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using the vaccine. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of her condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the event herpes zoster ophthalmicus was not recovered and causal relationship was assessed as related.   The lawyer considered the event herpes zoster ophthalmicus to be disability.   Upon internal review, the event herpes zoster ophthalmicus was determined to be medically significant.
As of 20SEP91 7 out of 28 staff members failed to respond to a series of 3 Engerix vax; titers were tested 4 months p/the last dose of Engerix-B given;
My son's thigh became swollen about six hours after, tripling in size.  It was bright red and hot to the touch. He was hysterical. We went to Urgent Care at Hospital and were told to give Benadryl and Motrin.  It took about 4 days to reduce swelling and return to normal.
Pain, but not as bad as day 1. Warm, red patch with one bump in the center, about 5 in long and 3 in across. The bump is sometimes itchy.
Began evening of injection - very sore. Difficult to move arm due to pain 24h later.
Pfizer vaccine was diluted incorrectly.  Client states his arm is sore but other than that he feels fine.
Face swollen,  sore knee swollen, arthritic fingers swollen, stubbed toe swollen, nausea, and tiredness
Mother told that baby was with father and he noted jerking movements of baby upper limbs and rest of baby, he had froth around mouth and tongue. Eyes rolled upward and he was unresponsive like.
No adverse reaction, patient was given high dose at age 62 when patient was supposed to receive the flublok.
PATIENT RECEIVED THE ADULT 30MCG DOSE INSTEAD OF 10MCG DOSE
fever; swollen enlarged lymph nodes; a burning rash on her neck and face; layers of skin that would peel off/ ears were peeling; her ears were inflamed; her ears were itchy; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): 2023NVX-US-000001270.  A 69-year-old female patient received bnt162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE), for COVID-19 immunisation, reaction(s): "achy"; Bnt162b2 (DOSE 1, SINGLE), for COVID-19 immunization, reaction(s): "fever". The following information was reported: RASH (non-serious) with onset 2022, outcome "unknown", described as "a burning rash on her neck and face"; PYREXIA (non-serious) with onset 2022, outcome "unknown", described as "fever"; EAR INFLAMMATION (non-serious) with onset 2022, outcome "unknown", described as "her ears were inflamed"; EAR PRURITUS (non-serious) with onset 2022, outcome "unknown", described as "her ears were itchy"; SKIN EXFOLIATION (non-serious) with onset 2022, outcome "unknown", described as "layers of skin that would peel off/ ears were peeling"; LYMPHADENOPATHY (non-serious) with onset 2022, outcome "unknown", described as "swollen enlarged lymph nodes". The events "fever", "swollen enlarged lymph nodes" and "a burning rash on her neck and face" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: After the 2nd dose, the patient had a fever, swollen enlarged lymph nodes and a burning rash on her neck and face. She went to the doctor and they scanned her lymph nodes since they were enlarged. She also had layers of skin that would peel off and her ears were inflamed, itchy and peeling. She had these symptoms that would come and go for 10 months.   The information on the batch/lot number for bnt162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-PV202300176225 Same patient, different AE/vaccine dose;
Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 51-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 08-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 08-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications was reported. No treatment medications was reported.
Information was received from a nurse concerning a first grade student who on 19 MAR 1999 was vaccinated with a dose of Varicella.  On 16 DEC 2004 the student developed chickenpox.  According to the school nurse there were 58 other elementary school students and 34 of them had previously been vaccinated with a dose of Varicella.  Unspecified medical attention was sought.  There was no information regarding the present status of the first grade student.  No product quality complaint was involved.  Additional information was requested.
it became much greater in numbers of rashes.; This is a spontaneous report from a contactable Consumer(patient). A 54-year-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: unknown) via an unspecified route of administration on Left arm on 09Mar2021 at 03:15 PM as dose 2, single for COVID-19 immunization (age at vaccination 54 years). The patient's medical history included lung cancer from 2016 (cured) chronic lyme disease and allergies to Doxycycline. Concomitant medication within 2 weeks of vaccination included nexuim, Organixx supplements and crestor. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested positive for COVID-19 since having the vaccine. Patient had not received any other vaccines within 4 weeks prior to the COVID vaccine. Historical vaccine included first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: unknown) via an unspecified route of administration on Left arm on 16Feb2021 at 02:30 PM(at the age of 54-years) as a dose 1, single for COVID-19 immunization and experienced Itchy, painful rash, Moves to different areas of body about every 24-36 hrs, a couple of the rashes have stayed in one spot, wrist and groin area and Some of the rash is barely visible, but extremely itchy, some is pink circle patches sized from nickel to quarte not as painful, just as itchy. After second dose, on 09Mar2021 same evening it became much greater in numbers of rashes. Events assessed as non-serious. No treatment received for the events. The clinical outcome of the event was not resolved.  Information about lot/batch number cannot be obtained. No further information expected.
no additional AE reported; female patient was administered a pediatric dose of VAQTA at a younger age than recommended; This spontaneous report has been received from a non-health care professional and refers to a 12-week-old female patient.  The patient's medical history, concurrent conditions, concomitant therapies and previous drugs reactions or allergies were not reported.  20-OCT-2022, the 12 weeks old patient was vaccinated with  first dose of hepatitis a vaccine, inactivated (VAQTA) at a dose of 0.5 ml, lot #CN3GS upon internal validation was found not valid for  hepatitis a vaccine, inactivated (VAQTA) expiration date reported: 19-NOV-2023,  administered for prophylaxis (vaccination scheme and route of administration were not provided)at a younger age than recommended within the prescribing information (Inappropriate age at vaccine administration). No additional adverse event were reported.
My face and neck turned very red, my eyes were slightly puffy.  I took 3 doses of Benedryl before it subsided
No adverse effects reported.; TE with PROQUAD from 8/19/2022. Administered to this patient on 9/26/2022; This spontaneous report has been received from an unspecified reporter, reporting to a 7-year-old patient of unknown gender. Information regarding medical history, concurrent conditions and concomitant medication was not provided.  On 26-SEP-2022, the patient was vaccinated with incorrect store dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live rHA (PROQUAD) injection, lot # U039261, expiration date 09-JUN-2023, 0.5 milliliter for prophylaxis (route of administration not reported). No adverse effects reported.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2308USA000495:02439769 US-009507513-2308USA000450:02439770 US-009507513-2308USA000144:02439771 US-009507513-2308USA000432:02439807 US-009507513-2308USA000185:02439808 US-009507513-2308USA000637:02439801 US-009507513-2308USA000669:02439777
Reactive arthritis in both knees , doctor indicated to wait longer to do second dose or to not get it at all , treatment - cut down on inflammatory foods
Case PHEH2016US024792 is an initial spontaneous report received from a pharmacist on 21 Sep p2016. This report refers to 58 year male patient. Medical history and concomitant medication was not reported. The patient was vaccinated with single dose of FLUVIRIN (batch number: 1618701, expiry date: not reported) at a dose of 0.5 ml intramuscular on 20 Sep 2016. On the same day, the patient had vaccine error patient was administered vaccine after temperature excursion. No adverse event was reported following this medication error.
Patient calls in reporting new fast breathing, fever, diarrhea, vomiting, chills, muscle aches, shaking/chills
Gave patient a shot on 9/8/17 at 11:22am (right deltoid); patient called and reported on 9/10/17 at 10am; patient had stiff neck/ pain, can not turn her head either left or right; no swelling or pain at injection site; no arm or shoulder pain.
Patient developed an urticarial reaction the day after he received his first dose of the Pfizer COVID-19 vaccine.  The rash was generalized throughout his entire body.  His face was also swollen.
After getting the vaccine patient felt light headed and fainted while sitting down. After being lifted to ground, patient appeared to seize. Seizure lasted less than 30 seconds. Patient regained consciousness immediately.
IMZ AT 1200 SATURDAY AND BY 5PM SHE SAID SHE ALMOST FELT "PARALYZED" AND "FELT LIKE SHE WAS GOING TO BREAK WITH EACH STEP"; SHE ALSO REPORTED A HEADACHE AND A "FEVER" IN HER ARM AND SWOLLEN ARM; SHE SAID IT WAS BETTER ON SUNDAY, AND STILL SWOLLEN ON MONDAY BUT NOT AS BAD AND OTHER SYMPTOMS SIGNIFICANTALLY LESS. PT DID NOT SEEK OUT ANY MEDICAL ATTENTION AS OF YET.
Patient received the Moderna vaccine on 12/29/20 and had pain at site for two days and went away. Two days ago (Wednesday 1/06/21), she noticed the site on her left arm is a bit reddened and did become a little painful like after receiving the vaccine. She have been taking ibuprofen but the redness has not gone away till now.
Swollen both eyes. Hives.  Hives never fully go away. Will fade, but can still see it. Can go from little Hives to full leg , arms, back. Eye swelling comes up about every three weeks.  Hives will not go away with over the counter allergy medicine, prescribed allergy medicine or steroids.
bursitis came back since the last couple of months; This spontaneous case was reported by a consumer and describes the occurrence of BURSITIS (bursitis came back since the last couple of months) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Bursitis (on and off since 7 years ago). Concomitant products included CORTISONE for Bursitis.   In March 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In 2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced BURSITIS (bursitis came back since the last couple of months). At the time of the report, BURSITIS (bursitis came back since the last couple of months) outcome was unknown.            No treatment information were given.
This spontaneous social media report was received from an article published in newspaper and refers to a 12-year-old female patient. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On an unknown date (reported as in September), the patient was vaccinated at school with a dose of GARDASIL (dose, route of administration and lot number were not provided) for prophylaxis. Next day, her legs felt heavy and she had a burning sensation in her spine. The straight student went on to lose all sensation in her legs, body and arms. On an unknown date, the patient found herself unable to move and just weeks later she was paralyzed from the neck down and in the hospital. The patient's family claimed she had suffered an alleged reaction to the HPV vaccine. However, her doctors claimed that her problem was completely psychological and the only help they offered was to section the patient. The patient's health deteriorated rapidly. At the time of the reporting, she shuffled before lying in her adapted bed at home, unable to move. The outcome of the events was unknown. The relatedness between vaccination with GARDASIL and the events was not reported. Upon internal review, the event of paralysis was considered to be medically significant. This is one of two reports received from the same source, as no contact details were provided. Additional information is not expected. Sender's Comments: US-009507513-1704USA006347.
This spontaneous report as received from a healthcare worker refers to an unspecified patients of unknown age and gender. Concurrent conditions and medical history were not reported. On an unknown date, the patients were vaccinated with an improperly stored dose of (Oka-Merck) PROQUAD (Lot#K010211, expiration date 17-JAN-2016; lot# L005297, expiration date 17-AUG-2016; lot#L010142, expiration date 24-SEP-2016; lot# L027634, expiration date 21-JAN-2017; or lot#L031602, expiration date 18-FEB-2017). (Strength, dose and route were not provided). Concomitant medications was not reported. No adverse effects reported. This is one of several reports from the same source. Additional information has been requested.
Patient developed small urticarial lesions proximal to injection site up towards neck.  No respiratory symptoms or other signs of an allergic reaction.
Rash-to upper chest and neck, chin, check and above eyes. Itching, raised small bumps.